Kornimate/medical-research-clean huggingface dataset:
study of osi-774 (tarceva) in previously untreated elderly lung cancer patients

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the primary purpose of this study is to determine whether the drug osi-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

patients will receive osi-774 once daily without interruption. there are no pre-determined number of cycles or planned dose interruptions. for the purposes of evaluation, toxicity and efficacy, a four week (28 day period) will be considered 1 cycle. patients will continue to receive osi-774 until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study. patients will have radiographic evaluations after every two cycles of therapy. after cycle 2, patients will also be evaluated by fdg-pet scanning. patients will also be asked to fill out a lung cancer symptom scale (lcss) on the first day of each cycle. bloodwork will also be performed on day 1 of each cycle as well as at the end of the study.

Eligibility criteria:
inclusion criteria: * age: 70 years of age or older * stage iv or iiib non-small cell lung cancer (nsclc) * measurable tumor(s) * three or more weeks since prior radiation therapy * three or more weeks since prior major surgery * must at least be able to walk and capable of taking care of oneself although unable to carry out work activities. * must be up and about more than 50% of waking hours. * life expectancy of 8 weeks or more * blood tests that show kidneys, liver and bone marrow to be working adequately * completely healed from previous oncologic or other major surgery exclusion criteria: * prior chemotherapy regimen for non-small cell lung cancer * prior exposure to osi-774 or similar treatments such as trastuzumab, zd1839, c225, etc. * uncontrolled central nervous system metastases * concurrent active cancer * malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * prior chemotherapy for any malignant disease * difficulty swallowing * a disease or disorder that interferes with ability to digest and absorb food * a medical condition that could make it unsafe for patient to participate in this study

Keywords: non-small cell lung cancer elderly cancer patients tarceva erlotinib osi-774 stage iiib or iv non-small cell lung cancer
oral status of patients suffering from schizophrenia followed at charles perrens hospital

Conditions: Dental Diseases; Schizophrenia

Summary: the aim of the study is to describe the oral health status of patients suffering from schizophrenia and schizoaffective disorders in a psychiatric institute in france.

schizophrenia concerns 21 million people in the world and 600 000 in france according to the world health organization. this pathology decreases the patient's quality of life and one patient out of two will try to commit suicide and 10% will die. oral health is an important factor for general well being. the litterature shows that schizophrenic patients tend to visit less dental surgeries than the general population. patients will often visit the surgery in emergency and dentist often choses to extract instead of a restorative solution. thus, schizophrenic subjects are 3,4 more likely to become edentulous compared to the general population. this is a cross-sectional epidemiological study on patients suffering from schizophrenia and and schizoaffective disorders in a psychiatric institution. a dental assessment will be conducted to provide clinical data on oral health. (dmft, hygiene, mouth dryness, prosthesis) and a survey of their diet, medication, oral quality of life, social security coverage and patients view regarding dental care (anxiety and healthcare renunciation). this is an observational study (oral examination and survey), so no treatment will be compared. the oral health status will be evaluated during one single oral examination and survey during the patient's stay at hospital.

Eligibility criteria:
inclusion criteria: * schizophrenic patients and patients with schizoaffective disorders at the charles perrens hospital * willing to participate in the study * 18 years old and above exclusion criteria: * patients mentally unable to participate or refusing to participate in this study. * patient hospitalized under duress * minor * patients unable to read, speak or write french

Keywords: schizophrenia psychiatric institutions epidemiology schizophrenic disorder oral health
comparison of the immediate effects of a hypopressive abdominal exercise program versus a proprioceptive neuromuscular facilitation stretching program on hamstring flexibility in adults with short hamstring syndrome

Conditions: Exercise Therapy; Physical Therapy Modalities; Hamstring Muscles

Summary: a randomised controlled trial was conducted to assess increases in hamstring flexibility using two different methods, one group of participants who were stretched with pnf techniques and the other group who performed hypopressive abdominal techniques (hat). flexibility scores of both groups were obtained and compared using pre and post measurements of a single intervention.


Eligibility criteria:
inclusion criteria: * participants with less than 75° in the straight leg raise test. exclusion criteria: * history of hamstring injury within the last year. * pharmacological treatment or history of neurological, orthopaedic, growth or autoimmune disorders. * training to improve flexibility in the week prior to the intervention. * hypertension. * pregnant women. * inability to perform hypopressive abdominal techniques.
retinal and choroidal circulation changes following rapid ascent to a high altitude environment

Conditions: High Altitude Retinopathy

Summary: this is a prospective observational study. the purpose is to explore the effect of high altitude hypobaric hypoxia on retinal microcirculation and the change of the thickness of the retina and choroid by optical coherence tomography angiography (octa).

yushu is in qinghai-tibet plateau, an average altitude of 4000 m. the medical staff is limited in yushu. zhongshan ophthalmic center, sun yat-sen university in yushu blindness project has lasted many years. some medical staff who arrived at yushu will have a plateau response. the high altitude hypoxia on retinal microcirculation evaluated by octa has not been reported. the aim of the study is to observe the microcirculation changes after exploring a hypobaric and hypoxia environment using octa, and relation with the plateau response. octa is a non-invasive examination and could see the microcirculation of the fundus directly and quickly.

Eligibility criteria:
inclusion criteria: 1. the subjects who plan to go to yushu within one month. 2. did not live on the high altitude of more than 1000 meters within 6 months. exclusion criteria: 1. unable and unwilling to provide informed consent. 2. any ocular disease may influence the retinal and choroidal circulation.
nutritional supplementation in geriatric hip fractures

Conditions: Geriatric Hip Fracture

Summary: this study is a randomized controlled trial comparing outcomes between geriatric hip fractures who received a commercially available (xr recoverytm, salt lake city utah) peri-operative nutritional supplement for three weeks post-operatively to those who receive standard nutritional counseling. the main question it aims to answer is: - does supplementation decrease muscle loss via ultrasound measurements of the cross-sectional area of the rectus femoris of the uninjured leg?


Eligibility criteria:
inclusion criteria: 1. male or female, aged 65 years or older. 2. presenting with a geriatric hip fracture (femoral neck, intertrochanteric, or subtrochanteric) requiring surgical intervention. 3. able to provide informed consent. 4. expected to survive at least 6 months after surgery, with no terminal illness. exclusion criteria: 1. pre-existing conditions that significantly impair mobility prior to injury. 2. severe renal or liver impairment. 3. active treatment with investigational drugs or participation in another clinical trial within the last 30 days. 4. inability to tolerate oral nutritional supplementation due to gastrointestinal disorders. 5. allergies to any components of the nutritional supplement being tested.
observational study of hemiplegic shoulder pain after recent stroke

Conditions: Shoulder Pain; Hemiplegia; Stroke

Summary: this is an observational study to address the following questions. 1. how many people develop stroke-shoulder pain within 3 days of stroke? 2. how many people have stroke shoulder pain at 8-10 weeks after stroke? 3. does having stroke-shoulder pain within 3 days of stroke predict the likelihood of having stroke-shoulder pain at 8-10 weeks? 4. what are the best bedside examination tests to identify stroke-shoulder pain?

patients will be assessed very early after stroke (within 72 hours) and followed up 8-10 weeks later. findings will enable planning of fully-powered randomised controlled trials of both, pain-prevention strategies and treatment.

Eligibility criteria:
inclusion criteria: - clinical diagnosis of haemorrhagic or ischaemic stroke exclusion criteria: * transient ischaemic attack, * neurological symptoms due to causes other than acute stroke, * unconscious, * severe behavioural disturbance, * severe agitation, * severe dementia, * for palliation, * totally unable to communicate using any method - written, verbal, pictures, gesture
anesthesia and acute kidney injury after nephrectomy

Conditions: Nephrectomy

Summary: this study investigates the influence of type of anesthesia on postoperative renal dysfunction in patients undergoing nephrectomy. the participants will be allocated to either the group receiving the total intravenous anesthesia (tiva) using propofol or the group receiving the inhaled anesthetics using desflurane.

nephrectomy is considered as a standard therapy for renal cell carcinoma, but it can cause postoperative renal dysfunction, such as acute kidney injury and chronic kidney disease. therefore, it is imperative to identify modifiable risk factors for postoperative acute kidney injury after nephrectomy in advance. according to a recent retrospective study, total intravenous anesthesia using propofol is significantly associated with lower incidence of acute kidney injury after nephrectomy, compared to the inhalation anesthesia. however, there is no prospective study which investigates the influence of type of anesthesia on postoperative renal function after nephrectomy. therefore, in the present study, we aimed to investigate the influence of type of anesthesia on acute kidney injury after nephrectomy by performing randomized controlled study.

Eligibility criteria:
inclusion criteria: * adults patients scheduled for elective open nephrectomy exclusion criteria: * patients diagnosed with acute kidney injury preoperatively * patients who have chronic kidney disease over stage 5 (estimated glomerular filtration rate \[egfr\] \<15 ml/kg/1.73m2) or have regular hemodialysis preoperatively

Keywords: anesthesia propofol inhaled anesthetics acute kidney injury nephrectomy
body mass index and initial presentations of cardiovascular diseases

Conditions: Abdominal Aortic Aneurysm; Acute Myocardial Infarction; Stroke; Heart Failure; Peripheral Arterial Disease; Angina

Summary: the association between obesity and cardiovascular disease (cvd) has mostly been studied using broad endpoints or have focused on cause-specific mortality. the investigators aim to compare the effect of body mass index (bmi) on different types of initial presentation of cvd.

obesity has many detrimental effects on the cardiovascular system that can manifest in a range of clinical presentations. many of these are mediated by frequently coexisting conditions such as diabetes, hypertension and dyslipidemia but there are also direct, progressive effects on the arteries and the heart muscle. as evident from autopsies, even from early adulthood the degree of coronary artery disease (cad) correlates with the bmi and particularly the amount of abdominal fat. the multiple mechanisms by which obesity exerts its effects are still being elucidated. previous studies have assessed the effect of obesity on cause-specific mortality. here the investigators analyze association of bmi with the first symptomatic presentation of cardiovascular disease across any phenotypes, to which the investigators refer to as "initial presentation" to distinguish from first presentation within a specific phenotype. for example, an initial presentation with myocardial infarction is an mi which is not preceded by stable angina, ischemic stroke or any other phenotype, rather than the first mi in a possible series of mis, as is commonly used in other studies. adjustments the key risk factor of interest is baseline bmi, which the investigators define as the most recent measurement of bmi recorded up to 2 years prior to cohort entry date. bmi will be analyzed based on the following categories: underweight (\ 35 kg/m2). the healthy bmi category will be used as the reference in regression models. associations with bmi will be adjusted for age, sex, ethnicity, social deprivation, smoking, diabetes, and systolic blood pressure, total cholesterol (tchol) and high-density lipoprotein cholesterol (hdl). all baseline covariates will be obtained from within a 2 year window prior to study entry. statistical analyses cause-specific cox models will be used to measure the association between bmi categories and endpoints of interest. multiple imputation will be used to replace missing values in prognostic factors. the investigators will estimate lifetime risk for each endpoint over time adjusting for competing risks.

Eligibility criteria:
inclusion criteria: * baseline age ≥30 years exclusion criteria: * prior atherosclerotic disease or stroke

Keywords: abdominal aortic aneurysm acute myocardial infarction coronary heart disease not otherwise specified haemorrhagic stroke heart failure ischaemic stroke peripheral arterial disease stable angina unheralded coronary death unstable angina ventricular arrhythmias, cardiac arrest and sudden cardiac death transient ischemic attack
feasibility study of non-invasive and continuous measurement of blood pressure and cardiac output: comparison to non-invasive and non-continuous measurements

Conditions: Heart or Vascular Disease

Summary: the objectives of this clinical trial is to validate a s/w application to compare the calculations of hemodynamic parameters like continuous blood pressure (bp) and continuous cardiac output (co). this hemodynamic parameters are computed from pulse oximeter (photoplethysmograph or ppg) signal with results obtained by nibp intermittent measurements and echocardiography. the first phase of the study will be done on 10 patients of the cardiology dept.- cardiac icu, that have routine measurements of bp and co using echocardiography. the heartbeat system combines an fda/ce approved watch-like pulse oximeter for acquiring the data and a smartphone s/w application that serves as the hemodynamic calculator. the s/w application performs post-processing of the photoplethismographic (ppg) signal (normally the ppg signal in pulse oximeters is used only to compute heart rate and spo2). the raw data is transferred from the watch oximeter to the smartphone using a standard bluetooth protocol. the post-processing uses wavelet signal processing to estimate and display certain hemodynamic parameters like (blood pressure) bp and co in a continuous and graphical way on a standard android smartphone. in addition to the standard heart rate and spo2, the application displays the measured ppg signal and estimated continues bp and co. heartbeat is the only device that can non-invasively estimate continuous bp and its cardiac output component and the resistance component in a mobile wearable device. differentiating between these 2 components can play a major role in helping the doctor to understand the effect of cardiovascular medications and lifestyle interventions.


Eligibility criteria:
inclusion criteria: * male and females * between the ages of 20-70 years old exclusion criteria: * over 70 years old * under 20 years old * supportive blood pressure * severe sepsis * ventilated patients * supported by amines * patients in state of shock

Keywords: continues non-invasive blood pressure measurement continues non-invasive cardiac output measurement
τhe effect of lumbar spine mobilization and manipulation on pressure pain threshold in patients with nslbp

Conditions: Low Back Pain; Lumbago

Summary: manual therapy, including mobilizations and manipulations, appears to be as effective as other types of therapy for chronic low back pain. the aim of this cross-sectional study is to compare the effects of lumbar spine mobilization and manipulation on the pressure pain threshold in patients with non-specific chronic low back pain.

background: manual therapy, including mobilizations and manipulations, appears to be equally effective as other types of therapy for chronic low back pain. according to the orthopaedic section of the american physical therapy association (apta), there is evidence indicating that these techniques can reduce pain, improve spinal and hip mobility, and decrease disability in patients with low back pain. the aim of this study is to compare the effects of lumbar spine mobilization and manipulation on the pressure pain threshold in patients with non-specific chronic low back pain. methods: the present study will be a cross-sectional study in which participants will be men and women aged 18 to 60 years. the sample size was estimated by effect size, with a minimum of 27 participants required to provide statistically or clinically significant results. each subject will receive two interventions-mobilization or manipulation-on two different days, in a random order. the primary outcomes will be pain perception, including subjective pain intensity and pressure pain threshold. secondary outcomes will include the range of motion (rom) of lumbar spine flexion, extension, and lateral flexion. data will be collected before and after each intervention. assessors will use a digital algometer, an electronic inclinometer, and a numerical rating scale (nrs). anova and t-test calculations will be performed on data processed by spss version 25 to analyze results for all outcomes. the level of significance will be set at 5% (p = 0.05) with a confidence interval of 95% (ci = 95%).

Eligibility criteria:
inclusion criteria: * 18 to 60 years old * diagniosed with non specific low back pain * symptoms lasting for more than 12 weeks exclusion criteria: * spinal fractures, * neurological impairment due to herniated spinal disc, * spondylolisthesis, * joint degenerative diseases, * osteoporosis, * spinal infections, * cauda equina syndrome, * spinal tumors or bone marrow malignancies, * spinal surgeries * history of cancer, * use of steroids

Keywords: non-specific low back pain manual therapy hypoalgesia pressure pain threshold
a clinical trial comparing buprenorphine formulations for high potency synthetic opioid use

Conditions: Opioid Use Disorder

Summary: the goal of this clinical trial is to compare buprenorphine formulations (sublingual buprenorphine versus long-acting injectable buprenorphine) for treating opioid use disorder among individuals who use fentanyl and/or other high potency synthetic opioids. individuals aged 18-65 will be eligible for enrollment. the main questions it aims to answer are: are there differences in frequency of drug use after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine? are there differences in rates of sustained relapse after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine? investigators also seek to understand and explore: how factors like body fat, body weight, and quantity of fentanyl use before treatment influence treatment outcomes. how blood levels of buprenorphine and its metabolite norbuprenorphine early on in treatment may influence treatment outcomes. how factors like craving and opioid withdrawal symptoms influence treatment outcomes. participants will: complete a brief overnight hospital stay in an inpatient research unit. this hospital stay will enable participants to start treatment with either sublingual buprenorphine or injectable buprenorphine. provide blood and urine samples while on the inpatient unit and at follow up. complete in-person follow up visits at 1-,2-,3-,4-, 8- and 12-weeks after leaving the hospital to measure drug use, craving, withdrawal, quality of life, and physical health.


Eligibility criteria:
inclusion criteria: * aged 18 to 65 * voluntarily seeking treatment for opioid use disorder (oud) * consistent use of fentanyl or other high potency synthetic opioids * meets dsm-5 criteria for oud with at least moderate severity * able to provide written informed consent in english and willing to comply with study procedures exclusion criteria: * meets dsm-5 criteria for another substance use disorder as the primary diagnosis * has an active, unmanaged psychiatric condition that would make participation hazardous (e.g., acute, psychosis, current suicidality, current manic episode) * has an active, unmanaged medical condition that would make participation hazardous or preclude use of buprenorphine or ancillary medications for withdrawal (e.g., unmanaged hypertension, unmanaged diabetes, clinically significant abnormality on ecg, acute hepatitis) * buprenorphine or methadone treatment in the past 30 days * known allergy, hypersensitivity or intolerance to buprenorphine * pregnancy, lactation, or unwillingness to use adequate contraceptive methods * current physiological dependence on sedative-hypnotics or alcohol that would require medically supervised detoxification * liver function tests \> 2x the upper limit of normal * use of medications or herbal products with known cyp3a4 inhibition or induction properties in the past 30 days